The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

MRI or PET scans are not always covered by Medicare or even other insurance,” Ighodaro said. “If I, as a neurologist, cannot ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

Having trouble sleeping could signal issues with brain health in middle age. Researchers from the American Academy of ...

Dementia Diagnostic Markers Change With Time ... it could be an early warning sign of Alzheimer's disease. Researchers used MRI scans to find that ... Novel Biomarker Could Lead to Early Diagnosis ...

A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Healthy obesity is defined as having a BMI of 25 kg/m² or higher without metabolic diseases or with only one metabolic ...

There is a robust body of research on key differences in lifestyle that may contribute to differences in an aging brain. For ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...